PTAB Finds Favor In Court; Novartis Is Latest To Strike Out In Challenge
Executive Summary
Federal Circuit affirms US Patent Trial and Appeal Board decision against Gilenya composition patent a week after upholding board decision on Exelon Patch patents; court has reviewed 200 PTAB decisions and affirmed 158 of them.
You may also be interested in...
Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.
Novartis Exelon Patch Patent Battle: PTAB Can Disagree With District Court
Federal Circuit rejects Novartis argument that Patent Trial and Appeal Board unlawfully concluded Exelon patents were unpatentable after a district court upheld them.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.